Cited 1 times in
Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.